Jump to Main Content

Awards

Lymphoma Abstract Award Recipients

2018 Recipients

  • Elena Battistello
    École Polytechnique Fédérale de Lausanne
    Lausanne, Switzerland
    Multimodal Inhibition of BCR Signaling in DLBCL Impacts DLBCL Evolution
  • Joanne Dai
    Duke University
    Durham, NC
    Epstein-Barr Virus Latent Infection of B Cells Promotes Germinal Center-Like Apoptosis Resistance
  • Franziska Gehringer
    Institute of Physiological Chemistry
    Ulm, Germany
    Tight Regulation of the PI3K-AKT-FOXO1 Axis Is Essential for Maintenance of the Dark Zone Program and Survival of Burkitt Lymphoma
  • James Heward
    Barts Cancer Institute, Queen Mary University of London
    London, United Kingdom
    KDM5 Inhibition Is A Novel Therapeutic Strategy for the Treatment of KMT2D Mutant Lymphomas
  • Kallesh Jayappa
    Beirne B. Carter Center for Immunology Research, University of Virginia
    Charlottesville, VA
    Diverse Microenvironmental Agonists Generate Drug Tolerant Persister Phenotype and Cancer Cell Proliferation in B Cell Malignancies
  • Michael Jin
    Stanford University Medical Center
    Stanford, CA
    Circulating Tumor DNA as a Biomarker for the Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
  • Masaharu Kawashima
    Tokai University, Isehara-shi
    Kanagawa, Japan
    Upregulation of Immune Checkpoint Markers PDL1/2 on Monocytes Induced by Direct Contact With Hodgkin Cells
  • Gero Knittel
    University Hospital Cologne
    Cologne, Germany
    MYD88 p.L265P and BCL2 Overexpression Cooperate in Lymphomagenesis in Mice
  • Marvyn Koning
    Leiden University Medical Center
    Leiden, Netherlands
    Primary Cutaneous Follicle Center Lymphomas Express Heavily Mutated B-Cell Receptors With Acquired N-Glycosylation Motifs and Lack Ongoing Somatic Hypermutation
  • Olga Kutovaya
    BC Cancer
    Vancouver, Canada
    UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation Through A Cyclin D1 Dependent Mechanism
  • Marion Lacroix
    IRCM (Clinical Research Institute of Montreal)
    Montreal, Canada
    The Role of the RNA Helicase DDX3X in Human Burkitt Lymphoma
  • Anna Lollies
    Institute of Cell Biology (Cancer Research)
    Essen, Germany
    Molecular Mechanisms in the Pathogenesis of Composite Lymphomas
  • Kathryn Lurain
    National Cancer Institute, National Institutes of Health
    Washington, DC
    Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma With Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate
  • Sayeef Mirza
    University of South Florida
    Tampa, FL
    Genomic Landscapes of CTCL and Sezary Syndrome
  • Soumya Sundara Rajan
    University of Miami
    Miami, FL
    Genomic Editing of Transplantable Hematopoietic Stem Cells With CRISPR/Cas9 to Generate Npm1-Alk Through Chromosomal Translocation Accurately Models ALK+ T-Cell Lymphoma in Mice
  • Ariel Sindel
    VCU Health System
    Richmond, VA
    Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma
  • Vipul Shukla
    La Jolla Institute for Allergy and Immunology
    La Jolla, CA
    Tet Proteins Regulate Enhancer Function and Class Switch Recombination During B Cell Activation
  • Ashima Shukla
    Sanford Burnham Prebys Medical Discovery Institute
    San Diego, CA
    Change in B Cell Receptor Isotype Alters the Tumor Forming Properties of Lymphoma B Cells
  • Richard Sora
    Northwestern University Feinberg School of Medicine
    Glenview, IL
    Blocking Two Pathways of P27Kip1Degradation Delays Tumor Onset in Mouse Model of Myc-driven Lymphoma
  • Yasuhito Suehara
    University of Tsukuba
    Tsukuba, Japan
    Tp53 mutations Found in the Serum of Malignant Lymphoma Patients at Remission Derive From Clonal Hematopoiesis Rather Than Minimal Residual Disease
  • Justin Taylor
    Memorial Sloan Kettering Cancer Center
    New York, NY
    Oncogenic Mutations in XPO1 Promote Lymphoid Transformation by Altering Nuclear-Cytoplasmic Localization of NFκB Signaling Intermediates
  • Elena Viganò
    BC Cancer Research Centre
    Vancouver, Canada
    Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition
  • Jillian Wise
    Oslo University Hospital, Institute for Cancer Research
    Westport , MA
    Relapsed/refractory Diffuse Large B-Cell Lymphomas Demonstrate Late Divergent Evolution and Increased TP53 Network Aberrations
  • Julieta Sepulveda-Yanez
    Leiden University Medical Center
    Leiden, Netherlands
    Differential Mutational Pattern in Indolent B-Cell Lymphomas
  • Tetsumi Yoshida
    Hiroshima University
    Hiroshima, Japan
    Patterns of IgH Rearrangement Can Predict Prognosis of Diffuse Large B-Cell Lymphoma in Association With CDC25A Overexpression

2016 Recipients

  • Idit Sagiv-Barfi
    Stanford University
    Stanford, CA
    Which Checkpoint Antibody Combinations Are Synergistic?
  • Emilia Bialopiotrowicz, PhD
    Institute of Hematology and Transfusion Medicine
    Warsaw, Poland
    Functional Link Between Heat Shock Protein HSP90alpha and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B-Cell Lymphoma
  • Rebecca Boddicker, PhD
    Mayo Clinic
    Rochester, MN
    Integrated Mate-Pair and RNA Sequencing Identifies Novel, Targetable Gene Fusions in Peripheral T-Cell Lymphoma
  • Alexander Craig, MPhil
    Stanford University Medical Center
    Stanford, CA
    Methods of Circulating Tumor DNA Quantification in Plasma
  • Ondrej Havranek, MD, PhD
    The University of Texas MD Anderson Cancer Center
    Houston, TX
    Features of Tonic B-Cell-Receptor Signaling in Diffuse Large B-Cell Lymphoma
  • Keisuke Kataoka, MD, PhD
    Kyoto University
    Kyoto, Japan
    Novel Genetic Mechanism of Immune Evasion Involving PD-L1 in Aggressive Lymphomas
  • Marvyn Koning, BSc
    Leiden University Medical Center
    Leiden, Netherlands
    Autonomous, Antigen-Independent B-Cell Receptor Signaling in Non-GCB DLBCL
  • Robert Kridel
    BC Cancer Agency
    Vancouver, Canada
    Clonal Dynamics Shaping Histological Transformation and Progression in Follicular Lymphoma
  • Olga Kutovaya, PhD
    BC Cancer Agency
    Vancouver, Canada
    The Role of UBR5 Mutations in the Pathogenesis of Mantle Cell Lymphoma
  • Anja Mottok, MD
    BC Cancer Agency
    Vancouver, Canada
    Characterization of Genomic Rearrangements Involving CIITA and SOCS1 Using Targeted Capture Sequencing of Archival Tissue Specimens
  • Samuel Ng, MD, PhD
    Dana-Farber Cancer Institute
    Boston, MA
    Exploring RhoA G17V-Mediated T-Cell Dysfunction
  • Georgios Pongas, MD
    National Cancer Institute, National Institutes of Health
    Bethesda, MD
    Early Adaptive Responses of PI3K Activity Are Mediated Through PI3K-Alpha After PI3K-Delta Inhibition in ABC-DLBCL Cell Lines With MYD88 and CD79A or CD79B Mutations
  • Julie Ross, PhD
    Institut de Recherches Cliniques de Montréal (IRCM)
    Montreal, Canada
    Loss of Functional Miz-1 Impairs c-Myc-Dependent B Cell Lymphomagenesis
  • Florian Scherer, MD
    Stanford University Medical Center
    Stanford, CA
    Biopsy-Free Genotyping and Molecular Subtyping of Diffuse Large B-Cell Lymphoma
  • Lili Wang, MD, PhD
    Harvard Medical School
    Boston, MA
    Integrated Dissection of Genetic and Transcriptional Heterogeneity in CLL by Single Cell Analysis

2014 Recipients

  • Wendy Béguelin, PhD
    Weill Cornell Medical College
    New York City, NY
    EZH2 Cooperates With BCL6 to Induce Normal Germinal Center Reaction and Lymphomas Through Assembly of Non-Canonical PRC1 Complexes at Bivalent Chromatin Domains
  • Mariano Cardenas, PhD
    Weill Medical College of Cornell University
    New York, NY
    Identification of Targetable Functional Groups on BCL6 Dimer Allows Rational Design of Potent and Selective Inhibitors With Activity in GCB- and ABC-Dlbcls
  • Katerina Hatzi, PhD
    Weill Cornell Medical College
    New York, NY
    The Histone Demethylase LSD1 Acts as a BCL6 Corepressor in Germinal Center B Cells
  • Ondrej Havranek
    The University of Texas MD Anderson Cancer Center
    Houston, TX
    The B-Cell Receptor Is Required for Optimal Viability, Growth, and Chemotherapy Resistance of Diffuse Large B-Cell Lymphoma Cell Lines of the Germinal Center B-Cell Subtype
  • Chuanxin Huang, PhD
    Weill Cornell Medical College
    New York, NY
    The Bcl6 RD2 Domain Governs Commitment of Activated B-Cells to Form Germinal Centers
  • Yanwen Jiang, PhD
    Weill Cornell Medical College
    New York, NY
    Deep-Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse in B-Cell Lymphomas
  • Melanie Märklin, MSc
    University of Tuebingen
    Tuebingen, Germany
    NFAT2 Is a Crucial Regulator of Anergy in CLL
  • Jonathan Reichel
    Weill Cornell Medical College
    New York, NY
    Transcriptome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
  • Florian Schere, MD
    University Medical Center Freiburg
    Freiburg, Germany
    Comprehensive Assessment of the Potential Role of B-Cell Receptor Antigen Recognition in the Pathogenesis of Follicular Lymphoma
  • Sally Trabucco
    UMass Medical School
    Worcester, MA
    Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-Cell Lymphoma
  • Jiyuan Zhang, PhD
    Columbia University, Institute for Cancer Genetics
    New York, NY
    Inactivation of MLL2 Early During B Cell Differentiation Promotes Expansion of Mature Germinal Center B Cells: Implications for Lymphoma-Associated MLL2 Mutations